CoChat

Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

Open access
Spigel, David R., McCleod, Michael, Jotte, Robert M., Einhorn, Lawrence, Horn, Leora, Waterhouse, David M., Creelan, Ben, Babu, Sunil, Leighl, Natasha B., Chandler, Jason C., Couture, Felix, Keogh, George, Goss, Glenwood, Daniel, Davey B., Garon, Edward B., Schwartzberg, Lee S., Sen, Rohini, Korytowsky, Beata, Li, Ang, Aanur, Nivedita, Hussein, Maen A. · 2019 · Journal of Thoracic Oncology
Cited by 185

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

INTRODUCTION CheckMate 153 (NCT02066636) is a phase 3B/4 study assessing nivolumab in previously treated patients with advanced non-small cell lung cancer (NSCLC). Eligibility criteria allowed enrollment of patients with poor prognostic features of advanced age or diminished Eastern Cooperative Oncology Group performance status (ECOG PS), which are typically underrepresented in or excluded from randomized controlled trials. METHODS Patients with stage IIIB/IV NSCLC and an ECOG PS of 0-2 with disease progression after ≥1 systemic therapy received nivolumab (3 mg/kg every 2 weeks) until progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was the incidence of grade 3-5 treatment-related select adverse events (AEs). RESULTS Among 1426 treated patients, 556 (39%) were aged ≥70 years and 128 (9%) had an ECOG PS of 2. Median treatment duration was 3.2 months. Across subgroups and the overall population, incidences of grade 3-5 treatment-related select AEs (6-9%) and grade 3-4 treatment-related AEs (TRAEs; 12-14%) were similar. One grade 5 TRAE was documented. Median overall survival (OS) was comparable in the overall population (9.1 months) and patients aged ≥70 years (10.3 months), but lower in patients with an ECOG PS of 2 (4.0 months). Patient-reported outcomes generally improved. CONCLUSIONS Data from this large predominantly community-based study, which included patients aged ≥70 years and with an ECOG PS of 2, are consistent with registrational studies. As expected, the median OS for patients with an ECOG PS of 2 was lower than for the overall population, but comparable with historical data.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2019.05.010

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 185

Metadata

Authors
Spigel, D. R., McCleod, M., Jotte, R. M., Einhorn, L., Horn, L., Waterhouse, D. M., Creelan, B., Babu, S., Leighl, N. B., Chandler, J. C., Couture, F., Keogh, G., Goss, G., Daniel, D. B., Garon, E. B., Schwartzberg, L. S., Sen, R., Korytowsky, B., Li, A., Aanur, N., & Hussein, M. A.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2019-09
Volume
14
Issue
9
Pages
1628-1639
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2946456966
Cited by
185
References
2
FWCI
11.06
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153). https://app.cochat.ai/papers/10.1016/j.jtho.2019.05.010
The paper
Spigel, D. R., McCleod, M., Jotte, R. M., Einhorn, L., Horn, L., Waterhouse, D. M., Creelan, B., Babu, S., Leighl, N. B., Chandler, J. C., Couture, F., Keogh, G., Goss, G., Daniel, D. B., Garon, E. B., Schwartzberg, L. S., Sen, R., Korytowsky, B., Li, A., . . . Hussein, M. A. (2019). Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153). Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2019.05.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.